While neonatal ICV injection in mice may not be directly translationally relevant due to differences in developmental ages between mice and humans, the observed benefits to treated mice still provide proof of concept that AAV9 gene replacement therapy can normalize both epilepsy and cognitive behavioral phenotypes in Slc6a1 heterozygous and homozygous mice. This evidence concerns the gene SLC6A1 and epilepsy.